Covered recipient · General Payments record
JAY GOLDBERG
General Payments · PY2018–2022
$23,077.33
- Reported across 252 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2022 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $332.47 | 16 |
By paying entity
PY2022 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $173.21 | 7 |
| Myovant Sciences Inc. | $46.97 | 3 |
| PFIZER INC. | $36.73 | 2 |
| Daiichi Sankyo Inc. | $24.99 | 1 |
| Agile Therapeutics, Inc. | $23.53 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $18.08 | 1 |
| Channel Medsystems, Inc. | $8.96 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2022 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2022 2018201920202021
Record-level detail is published for PY2022; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.20 | 01/25/2022 | Food and Beverage | Undisputed | 01/23/2026 | 891048233 | CMS |
| ABBVIE INC. | $29.55 | 01/31/2022 | Food and Beverage | Undisputed | 01/23/2026 | 891048235 | CMS |
| ABBVIE INC. | $20.03 | 02/25/2022 | Food and Beverage | Undisputed | 01/23/2026 | 891048237 | CMS |
| ABBVIE INC. | $29.43 | 03/11/2022 | Food and Beverage | Undisputed | 01/23/2026 | 891048239 | CMS |
| ABBVIE INC. | $22.76 | 03/30/2022 | Food and Beverage | Undisputed | 01/23/2026 | 891048241 | CMS |
| ABBVIE INC. | $28.96 | 04/14/2022 | Food and Beverage | Undisputed | 01/23/2026 | 891048243 | CMS |
| ABBVIE INC. | $25.28 | 05/11/2022 | Food and Beverage | Undisputed | 01/23/2026 | 891048245 | CMS |
| Agile Therapeutics, Inc. | $23.53 | 01/19/2022 | Food and Beverage | Undisputed | 01/23/2026 | 957200205 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $18.08 | 02/23/2022 | Food and Beverage | Undisputed | 01/23/2026 | 930576721 | CMS |
| Channel Medsystems, Inc. | $8.96 | 04/11/2022 | Food and Beverage | Undisputed | 01/23/2026 | 921578077 | CMS |
| Daiichi Sankyo Inc. | $24.99 | 03/29/2022 | Food and Beverage | Undisputed | 01/23/2026 | 930826043 | CMS |
| Myovant Sciences Inc. | $13.92 | 01/06/2022 | Food and Beverage | Undisputed | 01/23/2026 | 941204571 | CMS |
| Myovant Sciences Inc. | $14.49 | 03/03/2022 | Food and Beverage | Undisputed | 01/23/2026 | 941204575 | CMS |
| Myovant Sciences Inc. | $18.56 | 05/10/2022 | Food and Beverage | Undisputed | 01/23/2026 | 941204577 | CMS |
| PFIZER INC. | $18.72 | 03/24/2022 | Food and Beverage | Undisputed | 01/23/2026 | 949085937 | CMS |
| PFIZER INC. | $18.01 | 05/24/2022 | Food and Beverage | Undisputed | 01/23/2026 | 949139501 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022
- Generated from
- OP_DTL_GNRL_PGYR2022_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.